Patents by Inventor Felix Cleemann

Felix Cleemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs comprising an aminoalkyl glycine linker
    Patent number: 11633487
    Abstract: The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising these prodrugs and the use of these prodrugs. A disclosed prodrug may include a biologically active moiety reversibly and covalently linked to a specialized protective group; the linker may be reversible (i.e., hydrolytically cleavable in the absence of enzymes under physiological conditions) and, upon cleavage, may release a drug in its unmodified, pharmacologically active form.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: April 25, 2023
    Assignee: ASCENDIS PHARMA A/S
    Inventors: Nicola Bisek, Harald Rau, Felix Cleemann, Thomas Knappe, Romy Reimann
  • PTH Prodrugs
    Publication number: 20230121525
    Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.
    Type: Application
    Filed: November 8, 2022
    Publication date: April 20, 2023
    Inventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
  • CNP PRODRUGS
    Publication number: 20230116746
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: June 23, 2022
    Publication date: April 13, 2023
    Inventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
  • CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY
    Publication number: 20230103820
    Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Application
    Filed: June 13, 2022
    Publication date: April 6, 2023
    Inventors: Kennett SPROGØE, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
  • CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS
    Publication number: 20220409700
    Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.
    Type: Application
    Filed: May 24, 2022
    Publication date: December 29, 2022
    Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
  • CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETY
    Publication number: 20220331438
    Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 20, 2022
    Inventors: Harald RAU, Ulrich HERSEL, Felix CLEEMANN, Caroline Elisabeth RASMUSSEN
  • CNP PRODRUGS WITH LARGE CARRIER MOIETIES
    Publication number: 20220296682
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Application
    Filed: November 15, 2021
    Publication date: September 22, 2022
    Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • CNP prodrugs with carrier attachment at the ring moiety
    Patent number: 11413351
    Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 16, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • Controlled-release CNP agonists with low initial NPR-B activity
    Patent number: 11389510
    Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 19, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
  • Controlled-release CNP agonists with reduced side-effects
    Patent number: 11389511
    Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 19, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
  • CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING
    Publication number: 20220211817
    Abstract: The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Application
    Filed: March 16, 2022
    Publication date: July 7, 2022
    Inventors: Harald Rau, Ulrich Hersel, Kennett Sprogøe, Frank Faltinger, Thomas Wegge, Felix Cleemann
  • Controlled-release CNP agonists with low NPR-C binding
    Patent number: 11311604
    Abstract: The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 26, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Kennett Sprogøe, Frank Faltinger, Thomas Wegge, Felix Cleemann
  • Liquid Pharmaceutical Formulations of PTH Conjugates
    Publication number: 20220088149
    Abstract: A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.
    Type: Application
    Filed: February 10, 2020
    Publication date: March 24, 2022
    Inventors: Anja R.H. SKANDS, Felix CLEEMANN, Michael Duelund SØRENSEN, Julia BARON, Eric HOFFMANN, Kennett SPROGØE
  • CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY
    Publication number: 20220088206
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Kennett SPROGØE, Harald RAU, Ana BERNHARD, Ulrich HERSEL, Felix CLEEMANN, Thomas WEGGE
  • PTH Prodrugs
    Publication number: 20220008516
    Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 13, 2022
    Applicant: ASCENDIS PHARMA BONE DISEASES A/S
    Inventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
  • CNP prodrugs with large carrier moieties
    Patent number: 11154593
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 26, 2021
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • CNP PRODRUGS WITH LARGE CARRIER MOIETIES
    Publication number: 20210177942
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • CNP PRODRUGS WITH LARGE CARRIER MOIETIES
    Publication number: 20210077584
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 18, 2021
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • CNP PRODRUGS
    Publication number: 20210069339
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: August 13, 2020
    Publication date: March 11, 2021
    Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
  • PTH PRODRUGS
    Publication number: 20200376089
    Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 3, 2020
    Applicant: Ascendis Pharma Bone Diseases A/S
    Inventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler